Myocarditis and Pericarditis After Vaccination for COVID-19
Open accessAbstract
This study investigates the incidence of myocarditis and pericarditis emergency department or inpatient hospital encounters before COVID-19 vaccine availability (January 2019–January 2021) and during a COVID-19 vaccination period (February-May 2021) in a large US health care system.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
95% of patients with myocarditis were admitted to the hospital for 3 days with 10% in the intensive care unit compared with only 35% of pericarditis patients admitted to the hospital and 3% in intensive care.
“Ninety-five percent of patients with myocarditis were admitted to the hospital for 3 days with 10% in the intensive care unit compared with only 35% of pericarditis patients admitted to the hospital and 3% in intensive care.”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [88]
The case-management table (shown under Abstract in our copy) supports the admission and intensive-care percentages: 95% and 10% for myocarditis, versus 35.1% and 2.7% for pericarditis. It reports a median myocarditis hospital stay of 2 days (IQR, 2–3), not 3 days. (LLM, conf=0.92)
Experimental — accuracy not yet measured80% of myocarditis cases occurred after the second dose of one of the RNA vaccines (Pfizer and Moderna) versus 60% of pericarditis cases occurred after a single dose or with Ad26.COV2.S vaccine, and 75% were men.
“They found that 80% of myocarditis cases occurred after the second dose of one of the RNA vaccines (Pfizer and Moderna) versus 60% of pericarditis cases occurred after a single dose or with Ad26.COV2.S (Johnson and Johnson) vaccine, and 75% were men.”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [88]
The Results and case-characteristics table (both labeled Abstract in our copy) support that 16 of 20 myocarditis cases (80%) followed a second dose of an mRNA vaccine and that 15 (75%) were men. The pericarditis figure is reversed: 22 of 37 cases (59.5%) followed a second dose, while 15 (40.5%) followed a first dose and 2 (5.4%) followed Ad26.COV2.S. (LLM, conf=0.93)
Experimental — accuracy not yet measuredSymptom onset after vaccination was early for myocarditis (median, 3-11 days), whereas for pericarditis symptoms, the median was 20 days after vaccination.
“Symptom onset after vaccination was early for myocarditis (median, 3-11 days), whereas for pericarditis symptoms, the median was 20 days after vaccination.”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [88]
The Results passage reports myocarditis onset at a median of 3.5 days after vaccination, with an IQR of 3.0–10.8 days. The table reports a median of 20 days for pericarditis. The claim gets the contrast right but incorrectly labels the approximately 3–11-day range as the myocarditis median. (LLM, conf=0.88)
Experimental — accuracy not yet measuredOther COVID-19 vaccine platforms associated with myocarditis/pericarditis include adenovirus-vector and attenuated live virus vaccines.
“Other COVID-19 vaccine platforms associated with myocarditis/pericarditis include adenovirus-vector and attenuated live virus vaccines (Tables S3 and S4). 88”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [88]
The Results and case table (both labeled Abstract in our copy; page unavailable) report two pericarditis cases after Ad26.COV2.S vaccination, supporting the adenovirus-vector part of the claim. They report no myocarditis cases after that vaccine, and the copy does not address attenuated live-virus COVID-19 vaccines. (LLM, conf=0.88)
Experimental — accuracy not yet measuredMyocarditis occurred primarily in young men under 40 years of age, while pericarditis occurred primarily in men over 50 years of age.
“Myocarditis occurred primarily in young men under 40 years of age, while pericarditis occurred primarily in men over 50 years of age.”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [88]
75% of patients with myocarditis received NSAIDs versus 49% with pericarditis.
“Seventy-five percent of patients with myocarditis received NSAIDs versus 49% with pericarditis.”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [88]
95% of patients who developed myocarditis were White compared with 84% of pericarditis patients.
“Ninety-five percent of patients who developed myocarditis were White compared with 84% of pericarditis patients.”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [88]
40% of patients with myocarditis were treated for heart failure versus 14% with pericarditis.
“Forty percent of patients with myocarditis were treated for heart failure versus 14% with pericarditis. 88”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [88]
A study of 40 hospitals over 2 million people distinguished between patients with myocarditis or pericarditis without myocarditis following COVID-19 vaccination.
“A study of 40 hospitals located in Washington, Oregon, Montana, and California of over 2 million people distinguished between patients with myocarditis or pericarditis without myocarditis (ie, not perimyocarditis) following the COVID-19 vaccination. 88”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., Loran, D., Hrncir, D., Herring, K., Platzer, M., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2833 · Cited by 536 · see citing works
Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination
Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., Parker, M. A., & Kim, R. J. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2828 · Cited by 341 · see citing works
Myocarditis Temporally Associated With COVID-19 Vaccination
Rosner, C. M., Genovese, L. D., Tehrani, B. N., Atkins, M. B., Bakhshi, H., Chaudhri, S., Damluji, A. A., de Lemos, J. A., Desai, S., Emaminia, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.055891 · Cited by 212 · see citing works
Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018
Su, J. R., McNeil, M. M., Welsh, K. J., Marquez, P. L., Ng, C. S., Yan, M., & Cano, M. V. (2021) · Vaccine · doi:10.1016/j.vaccine.2020.12.046 · Cited by 143 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Bautista García J, Peña Ortega P, Bonilla Fernández JA, et al. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19. Rev Esp Cardiol (Engl Ed). Published online April 27, 2021. doi:10.1016/j.recesp.2021. 03.009 · DOI
Cited by
Sorted by citations
Ndeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678 · see citing works
COVID-19, Myocarditis and Pericarditis
Fairweather, D., Beetler, D. J., Di Florio, D. N., Musigk, N., Heidecker, B., & Cooper, L. T. (2023) · Circulation Research · doi:10.1161/circresaha.123.321878 · Cited by 181 · see citing works
Buchan, S. A., Seo, C. Y., Johnson, C., Alley, S., Kwong, J. C., Nasreen, S., Calzavara, A., Lu, D., Harris, T. M., Yu, K., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.18505 · Cited by 157 · see citing works
Alami, A., Krewski, D., Farhat, N., Mattison, D., Wilson, K., Gravel, C. A., Farrell, P. J., Crispo, J. A. G., Haddad, N., Perez-Lloret, S., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-065687 · Cited by 44 · see citing works
- Authors
- Diaz, G. A., Parsons, G. T., Gering, S. K., Meier, A. R., Hutchinson, I. V., & Robicsek, A.
- Affiliations
- Providence Regional Medical Center Everett (US)
- Providence Research Network, Renton, Washington
- Providence Health & Services (US)
- Corresponding author
- Diaz, George A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-09-28
- Volume
- 326
- Issue
- 12
- Pages
- 1210
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC8340007
- OpenAlex
- W3189406732
- Cited by
- 430
- References
- 4
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 51 · 2023: 91 · 2022: 205 · 2021: 51
- FWCI
- 66.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- myocarditis, pericarditis, COVID-19 vaccines, vaccine adverse events, incidence, emergency department visits, hospitalization, SARS-CoV-2
- MeSH terms
- COVID-19, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Ad26COVS1, Adult, Aged, Female, Hospitalization, Humans, Male, Middle Aged, Montana, Myocarditis, Oregon, Pericarditis, Time Factors, Washington, Los Angeles, Incidence, Confidence Intervals, Poisson Distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
